ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
42 announcements with these filters
Rubicon Research Ltd has filed its quarterly shareholding pattern as of June 30, 2026, in compliance with SEBI Regulation 31. The report reflects recent ESOP allotment data.
Rubicon Research disclosed a US FDA inspection at its Pithampur facility, yielding 2 procedural observations. The company is confident in resolving them, with no impact on data integrity or operations.
Rubicon Research reports robust Q4 FY26 results with 44% revenue growth and 112% PAT growth. Strategy shifts toward direct Indian market presence via Arinna Lifesciences acquisition.
Rubicon Research delivered a strong Q4 FY26 with 44% revenue growth and 112% profit increase, driven by a robust product pipeline and stable pricing despite outsourcing manufacturing for excess demand.
Rubicon Research recommended a final dividend of ₹1.5 per equity share for FY2026. The record date and AGM schedule will be announced following future board approval.
Rubicon Research Limited filed its Annual Secretarial Compliance Report for the financial year 2026. The report confirms full compliance with SEBI regulations with no fines levied.
Rubicon Research extended the timeline for utilising ₹147.63 Crore in unutilised IPO proceeds until March 2027. This extension provides operational flexibility for strategic investments and debt repayment.
Rubicon Research approved a new Employee Stock Option Scheme 2026 covering 24,84,415 equity shares. The plan aims to incentivize employees across the company and its subsidiaries.
Rubicon Research (Q4 FY26) reported revenue of ₹5,139M (up 43.5% YoY) and PAT of ₹768M (up 111.8% YoY). Strategy focuses on specialty products and US nasal spray market leadership.
Rubicon Research Ltd reported revenue from operations of ₹513.9 Cr (+43.5% YoY) and net profit of ₹76.8 Cr (+112.2% YoY) for Q4 FY26.
Rubicon Research reported audited FY26 results and recommended a ₹1.50 per share dividend. The performance reflects steady growth and continued shareholder returns.
Rubicon Research scheduled a board meeting for May 29, 2026, to approve annual audited financial results. Directors will also consider a dividend recommendation for the fiscal year.